Prognostic and clinicopathological value of fibrinogen-to-albumin ratio in non-small cell lung cancer: a meta-analysis

Table 2 Subgroup analysis of the prognostic value of FAR for OS in patients with NSCLC

Subgroups	No. of studies	No. of patients	Effects model	HR (95%CI)	p	Heterogeneity I²(%) Ph		Meta-regression p-value
Total	7	2655	Fixed	1.82(1.56–2.14)	< 0.001	36.2	0.152
Sample size								0.357
< 270	3	545	Random	1.79(1.09–2.92)	0.021	66.1	0.053
≥ 270	4	2110	Fixed	1.99(1.62–2.46)	< 0.001	0	0.591
Study center								0.826
Single center	6	2243	Fixed	1.83(1.54–2.18)	< 0.001	48.6	0.094
Multicenter	1	412	-	1.79(1.23–2.61)	0.002	-	-
TNM stage								0.196
I-III	2	1428	Fixed	2.28(1.66–3.11)	< 0.001	0	0.414
III-IV	3	621	Fixed	1.82(1.43–2.32)	< 0.001	48.4	0.144
I-IV	2	606	Fixed	1.53(1.16–2.03)	0.003	31.9	0.226
Treatment								0.604
Surgical resection	2	1428	Fixed	2.28(1.66–3.11)	< 0.001	0	0.414
Chemotherapy	2	530	Fixed	1.72(1.34–2.20)	< 0.001	0	0.809
Others	3	697	Random	1.87(1.09–3.18)	0.022	67.1	0.048
Cut-off value								0.489
< 0.120	4	1882	Fixed	1.77(1.46–2.16)	< 0.001	47.6	0.126
≥ 0.120	3	773	Fixed	1.92(1.46–2.52)	< 0.001	42.3	0.177
Cut-off determination								0.501
ROC curve	6	2243	Fixed	1.83(1.54–2.18)	< 0.001	46.8	0.094
X-tile	1	412	-	1.79(1.23–2.61)	0.002	-	-
Survival analysis								0.287
Univariate	2	1496	Random	2.02(1.35–3.03)	0.001	60.1	0.113
Multivariate	5	1159	Fixed	1.74(1.42–2.14)	< 0.001	37.8	0.169

FAR, fibrinogen-to-albumin ratio; NSCLC, non-small cell lung cancer; OS, overall survival; ROC, receiver operating characteristic; TNM, tumor-node-metastasis

ISSN: 1477-7819